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Aim of this prospective study is to evaluate the expression of 
HIF-1 after RT and correlate it with the development of 
rectal mucosal angiectasias and bleeding.  
 
Material and Methods: Patients with histological proof of 
prostate cancer without distant metastases, undergoing a 
standard course of external beam radiation therapy (3D-RT), 
were considered eligible. Each patient underwent a 
rectosigmoidoscopy with bioptic sampling prior to and one 
month and one year after RT. The development of rectal 
mucosal angiectasias was graded according to the Vienna 
Rectoscopy Score (VRS). HIF-1 was evaluated by 
immunohistochemistry and western blot analysis; the mean 
number of blood vessels per field was also assessed. 
Radiation-induced side effects (e.g. rectal bleeding) were 
recorded during follow-up visits.  
 
Results: Thirty-one patients were enrolled (median age 72 
years, IQR 67-75). After the end of a median follow-up of 
19.8 months (IQR 18.4-20.9), 10 patients (32.3%) developed 
rectal bleeding needing intervention. All these patients 
presented a grade II or III VRS (p=0.03). The difference in the 
mean number of blood vessels between bleeders and not 
bleeders was not significantly different (p=0.47). The 
expression of HIF1 in bleeding patients was down regulated in 
2 cases, unchanged in 3 and up regulated in 4 cases (p>0.99); 
in one case it was not feasible to determine the expression. 
There was no correlation between the expression of HIF1 and 
the VRS.  
 
Conclusion: The expression of HIF1 does not correlate with 
the development of rectal mucosal angiectasias and bleeding 
in patients irradiated for prostate cancer. 
 
Poster: Radiobiology track: Biomarkers and biological 
imaging  
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Purpose or Objective: Subventricular zone-infiltrating (SVZ-
infiltrating) glioblastomas (GBMs) with subependymal spreads 
along ventricle walls are associated with decreased patient 
survival. The heterogeneity in patient survival and recurrence 
patterns of GBM with SVZ infiltration might be related to 
neuronal therapy resistant stem cells, located in the SVZ. It 
has not been systematically investigated if specific molecular 
genetic patterns of SVZ-infiltrating GBMs exist, and therefore 
are responsible for the unfavorable course after 
chemoradiation. 
 
Material and Methods: The current study assessed the 
molecularbiologic profile of 55 primary GBM cases that 
underwent chemoradiation. GBMs with SVZ infiltration and 
subependymal tumor spread (n = 24; 43.6 %) and peripherally 
located GBMs (n = 31; 56.4 %) were included. Genome 
methylation patterns were determined and copy number 
profiling was performed using an Illumina Infinium 
HumanMethylation450K (450K) Array, and the prognostic 
influence on progression and survival was evaluated. 
 
Results: The majority of patients showed the characteristics 
of a “classic” GBM subtype, independent of the tumor 
localization in regard of the SVZ, demonstrating a 
chromosome 7 gain and chromosome 10 loss, as well as 
deletion of Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A) 
and amplification of Epidermal Growth Factor Receptor 
(EGFR). Second, RTK I subtype, showing Platelet-Derived 
Growth Factor Receptor Alpha (PDGFRA) amplifications, 
could be detected equally in both groups. However, SVZ-
infiltrating GBMs with subependymal spreading showed a 
decreased overall survival (OS) compared to their peripheral 
counterparts. 
 
 
 
Figure: Genome wide copy number profiling of a classic 
primary gliolblastoma with chromosome 7 gain and 
chromosome 10 loss  
 
Conclusion: Genome methylation patterns were distributed 
independently of tumor localization in regard of the SVZ, 
suggesting that the biological entities in both GBM groups are 
identical. However, survival rates of GBMs with proximity to 
the SVZ were inferior and therefore the central localization 
seems to be responsible for the poor clinical courses. 
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Purpose or Objective: Evidence to support a role for the 
antidiabetic drug metformin in the prevention and treatment 
of cancer has emerged over the last decade. In particular, 
recent studies demonstrate that metformin enhances tumor 
response to radiation in experimental models. Metformin may 
therefore be of utility for nondiabetic cancer patients 
treated with radiation therapy. Despite being in clinical use 
for almost 60 years, the underlying mechanisms for 
metformins action remain elusive. We have therefore applied 
a novel PET-tracer, [11C]-metformin, to determine the 
uptake mechanism and elimination of the drug in vitro and in 
vivo. 
 
Material and Methods: To verify transporter-mediated 
uptake of metformin in tumor cells, a selection of cell lines 
were incubated with [11C]-metformin in the absence or 
presence of blocking unlabelled metformin. Two tumor 
models A549 (lung) and SiHa (cervix) was chosen for in vivo 
experiments. Mice bearing subcutaneous tumors in the lower 
back were administered ~10 MBq [11C]-metformin and 
dynamically PET scanned for 90 minutes. As a “proof of 
principle” experiments using PET/CT with [11C]-metformin 
organ specific uptake of [11C]-metformin was determined in 
healthy humans. Dynamic whole-body PET was performed on 
four healthy volunteers (2 male). Two minutes before scan 
start, a bolus injection of ~200 MBq [11C]-metformin was 
injected and five consecutive whole-body scans with 
increasing frame durations were obtained: 1, 1.5, 2, 2.5 and 
3 minutes per bed position. Time intervals for the PET scans 
were 2-8, 9-18, 19-32, 33-48 and 49-67 minutes (see figure 
1). Source organs for the dosimetry calculations were the 
liver, kidneys, salivary glands and the bladder. 
Results: In vitro metformin uptake varied widely but a high 
and inhibitable uptake was observed in A549 and SiHa cells. 
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Imaging with [11C]-metformin in tumor bearing mice showed 
a large uptake in the kidneys and excretion through the 
bladder, as expected for metformin. An uptake of [11C]-
metformin was seen in both A549 (lung) and SiHa (cervix) 
tumors and autoradiography supported this finding. 
Biodistribution of metformin in humans is shown in figure 1 
with visible uptake in liver, kidney and the salivary glands, 
but no detectable uptake in brain, muscle or adipose tissue. 
 
Conclusion: It is possible to visualize distribution of [11C]-
metformin in vivo. In xenograft models uptake in tumor was 
seen. It will be of great interest to investigate whether it is 
possible to visualize an uptake in human tumors, which will 
be done in a planned study in prostate cancer patients. 
 
 
 
Poster: Radiobiology track: Cellular radiation response  
 
 
PO-0995  
Osteopontin expression in glioblastoma – a promoter of the 
cancer stem cell-like phenotype? 
S. Rogers
1Kantonsspital Aarau, Radiation Oncology, Aarau, 
Switzerland 
1, R. Grobholz2, J. Berberat3, A.R. Fathi4, S. Bodis1 
2Kantonsspital Aarau, Pathology, Aarau, Switzerland 
3Kantonsspital Aarau, Neuroimaging, Aarau, Switzerland 
4Kantonsspital Aarau, Neurosurgery, Aarau, Switzerland 
 
Purpose or Objective: A high level of circulating osteopontin 
(OPN) at the end of radiotherapy (RT) is an adverse 
prognostic factor in patients with glioblastoma (GBM) and 
other tumours including rectum cancer. Recent mechanistic 
studies demonstrated HIF2α–mediated OPN/CD44 promotion 
of the glioma stem cell-like phenotype in a mouse model. 
Using unique paired tumour samples from patients with GBM, 
we investigated changes in levels of OPN protein expression 
following RT and compared these with rectum cancers from 
patients irradiated with the same pre-operative 
fractionation. 
 
Material and Methods: 3 patients with histologically 
confirmed GBM received pre-operative RT in an ethics-
approved Phase I trial. 2.5 Gy b.d. was delivered using IMRT 
over 5 days. Maximal safe tumour resection was performed at 
3, 5 and 10 days post RT in patients 1, 2 and 3 respectively. 
Immunohistochemistry was performed on the paired 
diagnostic biopsy and irradiated resection specimen using 
validated antibodies (rabbit polyclonal antibody to OPN: 
clone PA1-38332, Thermo Fisher Scientific) and an automated 
immunostainer. The staining was scored by a board-certified 
pathologist.  
 
Results: Levels of OPN in GBM tumour cells were high at 
baseline as compared with rectum adenocarcinoma. There 
was marked increase in OPN expression in response to RT in 
all three GBM tumours (Fig 1). Expression of Glut-1, a marker 
of intrinsic hypoxia and a target of HIF-2α, was not induced. 
Ki67 levels were reduced although levels of cyclin D1 
expression were unchanged. A dynamic contrast-enhanced 
(DCE) MRI performed on the last day of RT did not detect any 
change in tumour perfusion in any of the GBMs. Resection 
specimens from 3 rectum cancer patients irradiated 
preoperatively with the same schedule showed very low level 
induction of OPN. 
 
 
 
Conclusion: RT increased the levels of OPN expression in 
GBM tumour cells. This may be a direct effect or related to 
RT-induced changes in the hypoxic tumour microenvironment 
that were not detectable on a DCE-MRI or by Glut-1 
expression. Although RT significantly increases overall 
survival compared with surgery alone, particularly when 
combined with temozolomide, it may promote the cancer 
stem cell-like phenotype of residual GBM cells. Enhanced 
OPN/CD44 signalling in the perivascular niche is associated 
with resistance to therapy and blockade of this signalling 
pathway may prove of clinical benefit. The relative lack of 
induction of OPN expression in rectum cancer may explain 
the success of short course pre-operative RT in this tumour 
type. 
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Purpose or Objective: In process like reactive oxygen 
production and apoptosis mitochondria play an important role 
and both processes play also a significant role in radiotherapy 
(RT) response. Repair of RT induced damage is dependent on 
mitochondrial energy supply suggesting a role for 
mitochondrial DNA (mtDNA) in RT. mtDNA variations, such as 
mutations or depletion, might therefore influence RT 
response, as for example found in cisplatin-treated patients. 
Therefore carefully elucidating the effect of these processes 
in radiation response might be important. Hence, we 
hypothesize that reduced mitochondrial function enhances 
the radiation response as a consequence of reduced ATP 
production and increased cellular ROS exposure (Fig.1). 
